Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
16 Juni 2021 19:32:55
Lansoprazole na ujauzito
Lansoprazole ni dawa kundi la PPI inayofanya kazi ya kuzuia uzalishaji wa tindikali tumboni kwa kuzuia seli za parieto. Dawa hii hutumika kutibu vidonda vya tumbo, kucheua tindikali, kuungua umio kwa tindikali na magonjwa yatokanayo na uzalishaji mkubwa wa tindikali kama vile sindromu ya Zollinger-Ellison.
Taarifa za tafiti zinapendekeza kuwa dawa hizi zina hatari kidogo kwenye ujauzito, hata hivyo kuna taarifa chache za uzoefu wa matumizi kwa binadamu wajawazito. Kuna tafiti iliyoonyesha mahusiano ya aleji na pumu kwa watoto waliozaliwa na mama aliyetumia dawa hizi, hata hivyo inahitaji tafiti nyingine kufanyika ili kuhakiki. Madhaifu ya kiuumbaji kama madhaifu ya moyo yameonekana kuhusiana na matumizi ya dawa jamii ya PPI lakini hakuna ushahidi wa kisababishi cha moja kwa moja na tafiti zaidi zinahitajika kufnayika.
Endapo dawa hii itatumika kwa bahati mbaya au kwa makusudi kwenye kipindi cha kwanza cha ujauzito, hatari kwa kijusi tumboni inachukuliwa kuwa ndogo, hata hivyo watoto wanaozaliwa wanatakiwa kufuatiliwa kwa muda mrefu kuona nini kitatokea kwao.
Uzito wa dawa hii ni mdogo sana hivyo dawa ina uwezo wa kupita na kuingia kwenye maziwa na kumpata mtoto, licha ya kutokuwepo taarifa zinazoelezea matumizi kwa mama anayenyonyesha, dawa hii ni vema ikaepukwa kutumiwa kwa mama anayenyonyesha kwa jinsi inavyowezekana kutokana na tafiti za wanyama kuonyesha kuwa ina hatari ya kusababisha saratani na kuzuia uzalishaji wa tindikali kwa kiasi kikubwa.
Ushauri dhidi ya matumizi kwa mama mjamzito
Taarifa za binadamu zinaonyesha hatari kidogo ya madhara kwa kijusi-kichanga
Taarifa za binadamu zinaonyesha hatari kidogo ya madhara kwa kijusi-kichanga ina maana gani?
Kuna taarifa chache za uzoefu wa matumizi kwa binadamu kutoka kwenye dawa hii au dawa zilizo kundi moja au zinazofanana namna zinavyofanya kazi yake. Ikijumuisha ujauzito miezi mitatu ya kwanza, inaonyesha kuwa, dawa hii haiwakilishi kuwa na hatari yenye mashiko ya kuwa sumu kwa kichanga tumboni kuweza kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo endapo itatumika muda wowote ule kwenye ujauzito. Taarifa chache za uzoefu wa matumizi kwa binadamu zinafanya taarifa za uzazi wa wanyama kutokuwa na mashiko.
Ushauri wa matumizi kwa mama anayenyonyesha
Hakuna (chache) taarifa za binadamu- Inauwezekano mkubwa kuwa sumu
Hakuna (chache) taarifa za binadamu- Inauwezekano mkubwa kuwa sumu ina maana gani?
Hakuna taarifa za uzoefu kuhusu matumizi ya dawa hii kwa mama anayenyonyesha au kuna taarifa chache. Sifa za ufanyaji kazi wa dawa zinaonyesha kuwa dawa hii inaweza kuwa sumu kwa kichanga anayenyonya. Dawa hii isitumike kwa mama anayenyonyesha.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:20:49
Rejea za mada hii;
1. Product information. Prevacid. Tap Pharmaceuticals, 2001.
2. Schardein JL, Furuhashi T, Ooshima Y. Reproductive and developmental toxicity studies of lansoprazole (ag-1749) in rats and rabbits. Yakuri to Rinsho 1990;18:S2773–83. As cited in Shepard TH. Catalog of Teratogenic Agents. 8th ed. Baltimore, MD: Johns Hopkins University Press, 1995:245.
3. Schardein JL, Furuhashi T, Ooshima Y. Reproductive and developmental toxicity studies of lansoprazole (AG-1749) in rats and rabbits. Jpn Pharmacol Ther 1990;18(Suppl 10):119–29. As cited in Schardein JL. Chemically Induced Birth Defects. 2nd ed. New York, NY: Marcel Dekker, 1993:447.
4. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998;105:882–9.
5. Kallen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998;105:877–81.
6. Nielsen GL, Sorensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekbom A. The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther 1999;13:1085–9.
7. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 2002;47:1526–9.
8. Diav-Citrin O, Arnon J, Shechtman S, Schaefer C, Van Tonningen MR, Clementi M, De Santis M, Robert-Gnansia E, Valti E, Malm H, Ornoy A. The safety of proton pump inhibitors in pregnancy: a
multicentre prospective controlled trial. Aliment Pharmacol Ther 2005;21:269–75.
9. Mayer A, Sheiner E, Holcherg G. Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy. Arch Gynecol Obstet 2007;276:171–3.
10. Dehlink E, Yen E, Leichtner AM, Hait EJ, Fiebiger E. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. Clin Exp Allergy 2009;39:246–53.
11. Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541–5.
12. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010;363:2114–23.
13. Mitchell AA. Proton-pump inhibitors and birth defects—some reassurance, but more needed. N Engl J Med 2010;363:2161–3.
14. Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, Rasmussen SA, and the National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 2012;94:22–30.
15. Erichsen R, Mikkelsen E, Pedersen L, Sorensen HT. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. Am J Ther 2012 (Feb 3) [Epub ahead of print].
16. Matok I, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R. The safety of fetal exposure to protonpump inhibitors during pregnancy. Dig Dis Sci 2012;57:699–705.
17. Broussard CN, Richter JE. Treating gastro-oesophageal reflux disease during pregnancy and lactation. What are the safest therapy options? Drug Saf 1998;19:325–37.
18. Katz PO, Castell DO. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin N Am 1998;27:153–67.
19. Ramakrishnan A, Katz PO. Pharmacologic management of gastroesophageal reflux disease. Curr Treat Options Gastroenterol 2002;5:301–10.
20. Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin N Am 2003;32:235– 61.
21. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 2005;22:749–57.